BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:53 PM
 | 
Nov 05, 2007
 |  BC Extra  |  Company News

Gentium slips on defibrotide plans

GENT fell $1.41 to $17.23 on Monday after it said it plans to submit to FDA an amendment to the protocol of an ongoing Phase III trial of defibrotide to treat hepatic veno-occlusive...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >